Research Peptide
Buy Retatrutide Online
Retatrutide (LY-3437943) is a novel triple receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly and studied in late-stage clinical research for metabolic and weight-regulation endpoints. HerAmino supplies retatrutide as a lyophilized powder for in-vitro laboratory research use only.
99%+ purity
CoA per batch
Third-party tested
Research use only
What is retatrutide?
Retatrutide is a synthetic 39-amino-acid peptide engineered as a single molecule that activates three distinct incretin and metabolic receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor. This triple-agonist mechanism distinguishes it from the dual GLP-1/GIP agonist tirzepatide and the GLP-1-only agonist semaglutide.
Why researchers study retatrutide
Published phase 2 trials (NCT04881760) reported substantial changes in body weight and metabolic markers in adult cohorts, drawing wide research interest. Investigators are using retatrutide as a reference compound for receptor pharmacology, body-composition models, and comparative incretin-pathway studies.
Retatrutide vs tirzepatide vs semaglutide
- Semaglutide — GLP-1 receptor agonist (single pathway).
- Tirzepatide — GLP-1 + GIP dual agonist.
- Retatrutide — GLP-1 + GIP + glucagon triple agonist.
What you get from HerAmino
- Lyophilized retatrutide powder, 10mg or 30mg per vial.
- Independent third-party HPLC and mass-spec testing on every lot.
- Certificate of Analysis (CoA) included with every order.
- Discreet, plain packaging. Free domestic shipping over $150.
Reconstitution
Retatrutide is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water before use in laboratory protocols. See our bacteriostatic water reconstitution guide for the standard 0.9% benzyl alcohol diluent.
For in-vitro research use only. Not for human or veterinary consumption. Not a drug, supplement, or medical device. Not evaluated by the FDA.